{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 39,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "appendix",
  "function": "other",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style timeline to show the duration of IP protection for various therapeutic assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/36",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.78,
        "x": 0.19,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Timeline of patent and exclusivity coverage from 2006 to 2044",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2b62e6e-4a1f-4a34-abc8-3bf64c5650b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "framework",
      "text": "Gantt chart timeline",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c862c490-7b67-4ca4-8708-c8e82ac38e31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.18,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "list",
      "text": "Multi-Cytokine Technologies: 6 patent families, 33 issued patents, 44 applications pending",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e2a656b-d163-48e6-a724-2cf81595e447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.18,
        "x": 0.03,
        "y": 0.68
      },
      "kind": "list",
      "text": "Itolizumab: 11 patent families, 26 issued patents, 31 applications pending",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc3de550-5045-42b1-9067-16994cdd402b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.52,
        "y": 0.94
      },
      "kind": "paragraph",
      "text": "Itolizumab filings under exclusive license to Equillium for US, CA, AU, NZ. Cytokine Technologies are wholly owned and under prosecution in all major global markets",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c561326-97ef-41ee-911b-579216fd2e5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.35,
        "x": 0.16,
        "y": 0.91
      },
      "kind": "paragraph",
      "text": "Assumptions: Listed applications will issue; Biologics Exclusivity will be granted and will begin at NDA approval; Potential patent term extensions not shown",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb7c8b43-200c-4261-92a3-993e5e1e5433",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Equillium Intellectual Property & Regulatory Exclusivity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5bd60f3-4c18-46f4-b37f-7e3c4ef684a5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "2c8b7b2c-de99-4114-9ff2-5d7a16948f8d",
      "evidence": "Timeline visualization of overlapping patent and exclusivity periods",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 35,
      "beatId": "7e9cc88f-1575-42b8-8db4-7aeb85971bd0",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Team",
      "beatSlug": "sequoia-pitch-team",
      "evidence": "The deck presents information on Equillium's leadership team",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}